Income StatementBalance SheetCash FlowBusiness Segments
Eli Lilly logo

Eli Lilly Business Segments

Business, geographic, and product segment breakdowns

Eli Lilly generates $65.2B in annual revenue across 1 key segments: Reportable Segment ($65.2B). Based on the Q4 2025 filing.

Reportable Segment (TTM)$65.2B
Latest FilingQ4 2025
Report Date2026-02-12
Market Cap$784.58B
P/E Ratio38.01
ROE101.36%

Business Segments

Revenue

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$11.4B$13.5B$12.7B$15.6B$17.6B$19.3B

Cost of Sales

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$2.2B$2.4B$2.2B$2.4B$3.0B$3.4B

Marketing, selling, and administrative

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$2.1B$2.4B$2.5B$2.8B$2.7B$3.1B

Acquired in-process research and development

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$2.8B$189.2M$1.6B$153.8M$655.7M$528.8M

Other segment items

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$637.7M$1.1B$970.8M$1.2B$2.1B$1.8B

Net Income

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$970.3M$4.4B$2.8B$5.7B$5.6B$6.6B

Interest Income

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$47.8M$44.3M$48.3M$40.0M$65.0M—

Interest Expense

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$192.7M$224.7M$243.7M$249.0M$179.6M—

D&A

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$466.8M$484.8M$462.8M$478.5M$470.0M—

Asset impairment, restructuring, and other special charges

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$81.6M$344.0M$35.0M$0.0$364.9M—

Earnings (loss) in equity method investments

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$26.0M$24.2M-$58.7M-$16.0M$45.4M—

Income taxes (Note 14)

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$618.1M$628.9M$696.8M$1.1B$1.6B—

Expenditures for long-lived assets

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$1.5B$1.6B$1.5B$2.0B$2.3B$2.9B

Total Assets

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment—$78.7B$89.4B$100.9B$114.9B—

Equity Method Investments

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Reportable Segment$285.7M$285.7M$1.1B$39.8M$33.8M—

Products & Services

Revenue

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Net product revenue$10.6B$12.0B$11.6B$14.7B$16.3B$18.3B
Cardiometabolic Health$7.4B$9.1B$9.2B$11.3B$13.2B$14.5B
Mounjaro$3.1B$3.5B$3.8B$5.2B$6.5B$7.4B
Zepbound$1.3B$1.9B$2.3B$3.4B$3.6B$4.3B
Oncology$2.2B$2.6B$1.9B$2.4B$2.4B$2.6B
Verzenio$1.4B$1.6B$1.2B$1.5B$1.5B$1.6B
Immunology$1.2B$1.3B$1.1B$1.3B$1.4B$1.5B
Taltz$879.6M$952.0M$761.9M$847.6M$901.5M$1.1B
Trulicity$1.3B$1.3B$1.1B$1.1B$1.1B$1.0B
Other cardiometabolic health$1.0B—$944.8M$980.4M$1.1B$1.0B
Other oncology$324.3M$427.3M$788.6M$924.3M$937.4M$1.0B
Collaboration and Other Revenue$867.5M$1.5B$1.1B$831.7M$1.3B$991.7M
Jardiance$686.4M$1.2B$1.0B$690.0M$959.0M$768.6M
Other immunology$55.3M$77.3M$326.1M$408.0M$460.9M$489.0M
Neuroscience$351.8M$393.0M$272.1M$344.0M$315.7M$459.2M
Other$262.8M$190.7M$212.9M$201.5M$337.2M$191.4M

Potential achievements

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Ebglyss$1.3B$1.3B$1.3B$1.3B$1.3B$1.2B
Orforglipron$250.0M$250.0M$250.0M$250.0M$250.0M—
Boehringer Ingelheim——$610.0M—$410.0M—

Geographic

Loss Contingency Damages Awarded Value

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Brazil$30.0M$40.0M$1.4B$50.0M$50.0M—

Revenue

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
U.S.$7.8B$9.0B$8.5B$10.8B$11.3B$12.9B
Outside U.S.$3.6B$4.5B$4.2B$4.7B$6.3B$6.4B
Europe$1.6B$2.4B$2.4B$2.6B$3.5B$3.1B
Rest of world$1.1B$1.1B$997.4M$1.2B$1.7B$2.2B
Japan$429.1M$559.2M$402.2M$521.0M$554.7M$654.1M
China$459.9M$429.2M$450.8M$465.9M$560.4M$473.9M

Revenue Information Used To Determine Revenue Recognized Change In Accounting Estimate Percent

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
U.S.6.0%—1.0%1.0%1.0%—

Non-Current Assets

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
UNITED STATES And PUERTO RICO—$13.4B———$18.8B
Ireland—$3.2B———$4.3B

Long-Lived Assets

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Rest of world—$2.2B———$3.5B

Number of class action petitions

SegmentQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25
Israel———2.002.002.00

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.